TABLE 1 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 2 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 4 ASIA-PACIFIC NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 5 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 6 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 7 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 9 ASIA-PACIFIC REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 10 ASIA-PACIFIC NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA-PACIFIC NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 12 ASIA-PACIFIC INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA-PACIFIC NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 14 ASIA-PACIFIC INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 15 ASIA-PACIFIC GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 16 ASIA-PACIFIC PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 17 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 19 ASIA-PACIFIC NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 20 ASIA-PACIFIC NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 22 ASIA-PACIFIC NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 23 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 25 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 27 ASIA-PACIFIC DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 28 ASIA-PACIFIC ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS (HCMV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 31 ASIA-PACIFIC VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 33 ASIA-PACIFIC HEPATITIS B VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 35 ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC CORONAVIRUS INFECTION IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC OTHERS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021- 2030 (USD MILLION)
TABLE 42 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 44 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 46 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCT, 2021- 2030 (USD MILLION)
TABLE 49 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 51 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 52 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 53 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 54 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 55 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 56 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 57 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 58 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 59 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 60 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 61 ASIA-PACIFIC CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 63 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021- 2030 (USD MILLION)
TABLE 64 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY END USER, 2021- 2030 (USD MILLION)
TABLE 65 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)
TABLE 66 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 68 ASIA-PACIFIC INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 69 ASIA-PACIFIC NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 70 ASIA-PACIFIC M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 71 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 ASIA-PACIFIC NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 75 ASIA-PACIFIC NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 76 ASIA-PACIFIC INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 77 ASIA-PACIFIC NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 78 ASIA-PACIFIC INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 79 ASIA-PACIFIC GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 80 ASIA-PACIFIC PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 81 ASIA-PACIFIC HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 82 ASIA-PACIFIC NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 83 ASIA-PACIFIC NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 84 ASIA-PACIFIC NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 85 ASIA-PACIFIC NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 86 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 87 ASIA-PACIFIC MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 88 ASIA-PACIFIC HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 ASIA-PACIFIC DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 ASIA-PACIFIC ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 91 ASIA-PACIFIC HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 92 ASIA-PACIFIC VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 93 ASIA-PACIFIC DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 94 ASIA-PACIFIC RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 95 ASIA-PACIFIC RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 96 ASIA-PACIFIC FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 97 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 98 ASIA-PACIFIC GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 99 ASIA-PACIFIC CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 100 ASIA-PACIFIC ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 101 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 102 ASIA-PACIFIC ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 103 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 104 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 105 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 106 ASIA-PACIFIC TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 107 ASIA-PACIFIC SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 108 ASIA-PACIFIC LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 109 ASIA-PACIFIC SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 110 ASIA-PACIFIC PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 111 ASIA-PACIFIC CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 112 ASIA-PACIFIC NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 113 ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 114 JAPAN ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 115 JAPAN INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 116 JAPAN NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 117 JAPAN M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 118 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 JAPAN HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 JAPAN REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 121 JAPAN NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 122 JAPAN NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 123 JAPAN INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 124 JAPAN NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 125 JAPAN INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 126 JAPAN GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 127 JAPAN PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 128 JAPAN HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 129 JAPAN NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 130 JAPAN NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 131 JAPAN NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 132 JAPAN NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 133 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 134 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 135 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 136 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 137 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 138 JAPAN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 139 JAPAN ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 140 JAPAN HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 141 JAPAN VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 142 JAPAN DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 143 JAPAN RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 144 JAPAN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 145 JAPAN FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 146 JAPAN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 147 JAPAN GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 148 JAPAN CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 149 JAPAN ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 150 JAPAN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 151 JAPAN ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 152 JAPAN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 153 JAPAN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 154 JAPAN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 155 JAPAN TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 156 JAPAN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 157 JAPAN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 158 JAPAN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 159 JAPAN PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 160 JAPAN CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 161 JAPAN NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 162 JAPAN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 163 JAPAN ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 164 JAPAN ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 165 CHINA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 166 CHINA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 167 CHINA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 168 CHINA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 169 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 170 CHINA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 171 CHINA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 172 CHINA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 173 CHINA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 174 CHINA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 175 CHINA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 176 CHINA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 177 CHINA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 178 CHINA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 CHINA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 CHINA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 181 CHINA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 182 CHINA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 183 CHINA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 184 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 185 CHINA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 186 CHINA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 187 CHINA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 188 CHINA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 189 CHINA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 190 CHINA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 191 CHINA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 192 CHINA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 193 CHINA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 194 CHINA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 195 CHINA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 196 CHINA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 197 CHINA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 198 CHINA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 199 CHINA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 200 CHINA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 201 CHINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 202 CHINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 203 CHINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 204 CHINA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 205 CHINA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 206 CHINA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 207 CHINA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 208 CHINA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 209 CHINA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 210 CHINA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 211 CHINA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 212 CHINA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 213 CHINA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 214 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 215 SOUTH KOREA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 216 SOUTH KOREA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 217 SOUTH KOREA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 218 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 219 SOUTH KOREA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 220 SOUTH KOREA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 221 SOUTH KOREA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 222 SOUTH KOREA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 223 SOUTH KOREA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 224 SOUTH KOREA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 225 SOUTH KOREA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 226 SOUTH KOREA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 227 SOUTH KOREA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 228 SOUTH KOREA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 229 SOUTH KOREA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 230 SOUTH KOREA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 231 SOUTH KOREA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 232 SOUTH KOREA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 233 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 234 SOUTH KOREA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 235 SOUTH KOREA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 236 SOUTH KOREA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 237 SOUTH KOREA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 238 SOUTH KOREA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 SOUTH KOREA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 SOUTH KOREA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 241 SOUTH KOREA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 242 SOUTH KOREA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 243 SOUTH KOREA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 244 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 245 SOUTH KOREA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 246 SOUTH KOREA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 247 SOUTH KOREA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 248 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 249 SOUTH KOREA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 250 SOUTH KOREA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 251 SOUTH KOREA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 252 SOUTH KOREA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 253 SOUTH KOREA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 254 SOUTH KOREA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 255 SOUTH KOREA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 256 SOUTH KOREA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 257 SOUTH KOREA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 258 SOUTH KOREA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 259 SOUTH KOREA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 260 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 261 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 262 SOUTH KOREA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 263 INDIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 264 INDIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 265 INDIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 266 INDIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 267 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 INDIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 INDIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 INDIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 271 INDIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 272 INDIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 273 INDIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 274 INDIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 275 INDIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 276 INDIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 277 INDIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 278 INDIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 279 INDIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 280 INDIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 281 INDIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 282 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 283 INDIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 284 INDIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 285 INDIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 286 INDIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 287 INDIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 288 INDIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 289 INDIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 290 INDIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 291 INDIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 292 INDIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 293 INDIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 294 INDIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 295 INDIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 296 INDIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 297 INDIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 298 INDIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 299 INDIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 300 INDIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 301 INDIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 302 INDIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 303 INDIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 304 INDIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 305 INDIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 306 INDIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 307 INDIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 308 INDIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 309 INDIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 310 INDIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 311 INDIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 312 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 313 AUSTRALIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 314 AUSTRALIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 315 AUSTRALIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 316 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 AUSTRALIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 318 AUSTRALIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 319 AUSTRALIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 320 AUSTRALIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 321 AUSTRALIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 322 AUSTRALIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 323 AUSTRALIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 324 AUSTRALIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 325 AUSTRALIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 326 AUSTRALIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 327 AUSTRALIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 AUSTRALIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 AUSTRALIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 330 AUSTRALIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 331 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 332 AUSTRALIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 333 AUSTRALIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 334 AUSTRALIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 335 AUSTRALIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 336 AUSTRALIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 337 AUSTRALIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 338 AUSTRALIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 339 AUSTRALIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 340 AUSTRALIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 341 AUSTRALIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 342 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 343 AUSTRALIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 344 AUSTRALIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 345 AUSTRALIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 346 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 347 AUSTRALIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 348 AUSTRALIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 349 AUSTRALIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 350 AUSTRALIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 351 AUSTRALIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 352 AUSTRALIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 353 AUSTRALIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 354 AUSTRALIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 355 AUSTRALIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 356 AUSTRALIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 357 AUSTRALIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 358 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 360 AUSTRALIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 361 SINGAPORE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 362 SINGAPORE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 363 SINGAPORE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 364 SINGAPORE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 365 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 366 SINGAPORE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 367 SINGAPORE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 368 SINGAPORE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 369 SINGAPORE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 370 SINGAPORE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 371 SINGAPORE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 372 SINGAPORE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 373 SINGAPORE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 374 SINGAPORE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 375 SINGAPORE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 376 SINGAPORE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 377 SINGAPORE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 378 SINGAPORE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 379 SINGAPORE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 380 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 381 SINGAPORE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 382 SINGAPORE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 383 SINGAPORE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 384 SINGAPORE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 385 SINGAPORE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 386 SINGAPORE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 387 SINGAPORE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 388 SINGAPORE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 389 SINGAPORE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 390 SINGAPORE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 391 SINGAPORE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 392 SINGAPORE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 393 SINGAPORE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 394 SINGAPORE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 395 SINGAPORE ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 396 SINGAPORE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 397 SINGAPORE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 398 SINGAPORE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 399 SINGAPORE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 400 SINGAPORE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 401 SINGAPORE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 402 SINGAPORE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 403 SINGAPORE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 404 SINGAPORE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 405 SINGAPORE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 406 SINGAPORE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 407 SINGAPORE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 408 SINGAPORE ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 409 SINGAPORE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 410 THAILAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 411 THAILAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 412 THAILAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 413 THAILAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 414 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 415 THAILAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 416 THAILAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 417 THAILAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 418 THAILAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 419 THAILAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 420 THAILAND NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 421 THAILAND INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 422 THAILAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 423 THAILAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 424 THAILAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 425 THAILAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 426 THAILAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 427 THAILAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 428 THAILAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 429 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 430 THAILAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 431 THAILAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 432 THAILAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 433 THAILAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 434 THAILAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 435 THAILAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 436 THAILAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 437 THAILAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 438 THAILAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 439 THAILAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 440 THAILAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 441 THAILAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 442 THAILAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 443 THAILAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 444 THAILAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 445 THAILAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 446 THAILAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 447 THAILAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 448 THAILAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 449 THAILAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 450 THAILAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 451 THAILAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 452 THAILAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 453 THAILAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 454 THAILAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 455 THAILAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 456 THAILAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 457 THAILAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 458 THAILAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 459 MALAYSIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 460 MALAYSIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 461 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 462 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 463 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 464 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 465 MALAYSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 466 MALAYSIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 467 MALAYSIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 468 MALAYSIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 469 MALAYSIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 470 MALAYSIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 471 MALAYSIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 472 MALAYSIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 473 MALAYSIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 474 MALAYSIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 475 MALAYSIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 476 MALAYSIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 477 MALAYSIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 478 MALAYSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 479 MALAYSIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 480 MALAYSIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 481 MALAYSIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 482 MALAYSIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 483 MALAYSIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 484 MALAYSIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 485 MALAYSIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 486 MALAYSIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 487 MALAYSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 488 MALAYSIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 489 MALAYSIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 490 MALAYSIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 491 MALAYSIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 492 MALAYSIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 493 MALAYSIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 494 MALAYSIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 495 MALAYSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 496 MALAYSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 497 MALAYSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 498 MALAYSIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 499 MALAYSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 500 MALAYSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 501 MALAYSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 502 MALAYSIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 503 MALAYSIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 504 MALAYSIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 505 MALAYSIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 506 MALAYSIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 507 MALAYSIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 508 INDONESIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 509 INDONESIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 510 INDONESIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 511 INDONESIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 512 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 513 INDONESIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 514 INDONESIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 515 INDONESIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 516 INDONESIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 517 INDONESIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 518 INDONESIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 519 INDONESIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 520 INDONESIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 521 INDONESIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 522 INDONESIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 523 INDONESIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 524 INDONESIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 525 INDONESIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 526 INDONESIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 527 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 528 INDONESIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 529 INDONESIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 530 INDONESIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 531 INDONESIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 532 INDONESIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 533 INDONESIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 534 INDONESIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 535 INDONESIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 536 INDONESIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 537 INDONESIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 538 INDONESIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 539 INDONESIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 540 INDONESIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 541 INDONESIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 542 INDONESIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 543 INDONESIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 544 INDONESIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 545 INDONESIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 546 INDONESIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 547 INDONESIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 548 INDONESIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 549 INDONESIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 550 INDONESIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 551 INDONESIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 552 INDONESIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 553 INDONESIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 554 INDONESIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 555 INDONESIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 556 INDONESIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 557 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 558 PHILIPPINES INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 559 PHILIPPINES NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 560 PHILIPPINES M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 561 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 562 PHILIPPINES HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 563 PHILIPPINES REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 564 PHILIPPINES NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 565 PHILIPPINES INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 566 PHILIPPINES NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 567 PHILIPPINES INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 568 PHILIPPINES GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 569 PHILIPPINES PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 570 PHILIPPINES HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 571 PHILIPPINES NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 572 PHILIPPINES NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 573 PHILIPPINES NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 574 PHILIPPINES NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 575 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 576 PHILIPPINES MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 577 PHILIPPINES HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 578 PHILIPPINES DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 579 PHILIPPINES ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 580 PHILIPPINES HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 581 PHILIPPINES VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 582 PHILIPPINES DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 583 PHILIPPINES RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 584 PHILIPPINES RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 585 PHILIPPINES FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 586 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 587 PHILIPPINES GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 588 PHILIPPINES CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 589 PHILIPPINES ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 590 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 591 PHILIPPINES ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 592 PHILIPPINES SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 593 PHILIPPINES SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 594 PHILIPPINES LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 595 PHILIPPINES TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 596 PHILIPPINES SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 597 PHILIPPINES LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 598 PHILIPPINES SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 599 PHILIPPINES PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 600 PHILIPPINES CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 601 PHILIPPINES NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 602 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 603 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 604 PHILIPPINES ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 605 VIETNAM ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 606 VIETNAM INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 607 VIETNAM NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 608 VIETNAM M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 609 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 610 VIETNAM HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 611 VIETNAM REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 612 VIETNAM NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 613 VIETNAM NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 614 VIETNAM INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 615 VIETNAM NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 616 VIETNAM INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 617 VIETNAM GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 618 VIETNAM PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 619 VIETNAM HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 620 VIETNAM NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 621 VIETNAM NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 622 VIETNAM NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 623 VIETNAM NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 624 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 625 VIETNAM MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 626 VIETNAM HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 627 VIETNAM DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 628 VIETNAM ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 629 VIETNAM HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 630 VIETNAM VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 631 VIETNAM DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 632 VIETNAM RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 633 VIETNAM RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 634 VIETNAM FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 635 VIETNAM ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 636 VIETNAM GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 637 VIETNAM CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 638 VIETNAM ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 639 VIETNAM ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 640 VIETNAM ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 641 VIETNAM SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 642 VIETNAM SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 643 VIETNAM LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 644 VIETNAM TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 645 VIETNAM SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 646 VIETNAM LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 647 VIETNAM SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 648 VIETNAM PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 649 VIETNAM CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 650 VIETNAM NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)
TABLE 651 VIETNAM ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 652 VIETNAM ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 653 VIETNAM ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 654 REST OF ASIA-PACIFIC ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)